JMP Securities reaffirmed their buy rating on shares of Evelo Biosciences (NASDAQ:EVLO) in a research report sent to investors on Monday morning. The firm currently has a $25.00 target price on the stock.

Separately, Morgan Stanley increased their target price on Evelo Biosciences from $29.00 to $30.00 and gave the stock an overweight rating in a research report on Thursday, October 11th.

NASDAQ:EVLO opened at $10.89 on Monday. Evelo Biosciences has a 1 year low of $6.51 and a 1 year high of $16.75. The company has a debt-to-equity ratio of 0.09, a quick ratio of 17.86 and a current ratio of 17.86.

Evelo Biosciences (NASDAQ:EVLO) last posted its earnings results on Thursday, November 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.12. Research analysts expect that Evelo Biosciences will post -1.87 earnings per share for the current year.

Hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp purchased a new stake in shares of Evelo Biosciences in the second quarter worth $165,000. Northern Trust Corp purchased a new stake in shares of Evelo Biosciences in the second quarter worth $227,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Evelo Biosciences in the second quarter worth $267,000. Jane Street Group LLC purchased a new stake in shares of Evelo Biosciences in the second quarter worth $316,000. Finally, Dean Capital Investments Management LLC purchased a new stake in shares of Evelo Biosciences in the second quarter worth $436,000. Institutional investors own 82.08% of the company’s stock.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types.

Further Reading: What is the Federal Reserve?

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.